Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy

Launched by CENTRE HENRI BECQUEREL · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to plan radiation treatment for men with prostate cancer that has spread to the bones. The researchers want to see if using a special imaging technique called whole-body SPECT can help doctors better target the areas that need treatment. Stereotactic radiotherapy delivers precise radiation beams to small areas, and the trial aims to compare treatment plans based on traditional imaging methods with those using SPECT imaging.

To be eligible for this trial, participants must be men aged 18 or older who are generally in good health and have bone metastases from prostate cancer. They should also be able to provide informed consent and be part of a social security system. Participants will undergo routine imaging tests, including a bone scan using the VERITON-CT camera, which allows doctors to plan their treatment more accurately. Throughout the study, patients will receive standard care and follow-up as needed. It's important to note that those with certain medical conditions or who have had recent cancer treatment may not qualify for this trial.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years,
• • Good general health WHO ≤ 1
• • Informed and signed consent prior to any specific study procedure.
• • Patient affiliated to the social security system
• • Bone metastases from prostate cancer
• • Indication for bone stereotactic radiotherapy
• Exclusion Criteria:
• • Presence of active cancer in the previous three years
• • Protected adults (under guardianship or curatorship)
• • Unable to undergo medical monitoring for geographical, social or psychological reasons
• • Unable to decubitus (orthopnea, etc.),
• • Hypersensitivity to HDP or to one of the excipients of the radiopharmaceutical.
• • History of radiotherapy of the volume to be treated by stereotaxy.